Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 41Terminated 12Unknown 7Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors 1

Interventions

Paclitaxel 24Oxaliplatin 24Capecitabine 24Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Docetaxel 18Carboplatin 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Specimen Handling 9Pemetrexed 9Radiation 8Injections 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6Trastuzumab 6Topotecan 6Standard of Care 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Zoledronic Acid × Clear all
NCT06221072 2024-01-24

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Shanghai JMT-Bio Inc.

Phase 3 Not yet recruiting
1,360 enrolled

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡